Biological Activity:

BAY11-7082 is a potent and selective E2 ubiquitin (Ub) conjugating enzyme inhibitor. It inhibits the conjugation of Ub to a range of E2 enzymes and inhibits E2 enzyme mediated IκBα phosphorylation and indirectly decreases NF-κb activity. BAY11-7082 also reversibly activates MAPK signaling and induces apoptosis of leukemic T cell and B-cell lymphoma cell lines.

How to Use:

In vitro: BAY11-7082 was used at 10-20 µM final concentration in various assays.
In vivo: n/a

Reference:

• 1. Pierce JW, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. (1997) J Biol Chem. 272(34):21096-103.
• 2. Mori N, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary ***** T-cell leukemia cells. (2002) Blood. 100(5):1828-34.
• 3. Strickson S, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. (2013) Biochem J. 451(3):427-37.